“A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s94. doi:10.25251/skin.5.supp.94.